GlobalReach Health

January 21, 2020
Global Reach Health

Tepezza First Drug Approved to Treat Thyroid Eye Disease

January 21, 2020 – The U.S. FDA has approved TepezzaTM (teprotumumab-trbw), manufactured by Horizon Therapeutics, to treat thyroid eye disease (TED). It is the first and only FDA-approved therapy for this indication.
January 20, 2020
Global Reach Health

Monoferric Approved to Treat Anemia

January 20, 2020 – The U.S. FDA has approved MonoferricTM (ferric derisomaltose) injection, manufactured by Pfizer, to treat iron deficiency anemia in adult patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron, as well as adult patients who have
January 16, 2020
Global Reach Health

Rybelsus Label Update

January 16, 2020 – The U.S. FDA has approved an update to the label for Rybelsus® (semaglutide) tablets, manufactured by Novo Nordisk. The label now includes data from the PIONEER 6 cardiovascular outcomes trial demonstrating cardiovascular safety.
January 16, 2020
Global Reach Health

Ozempic Receives New Indication

January 16, 2020 – The U.S. FDA has approved a new indication for Ozempic® (semaglutide) injection 0.5mg or 1mg, manufactured by Novo Nordisk. Ozempic is now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as heart
January 14, 2020
Global Reach Health

New Safety Warning Regarding Belviq and Belviq XR

January 14, 2020 – The U.S. FDA has issued a safety communication regarding Arena Pharmaceuticals’ Belviq® (lorcaserin) and Belviq® XR (lorcaserin extended release). According to the agency, these drugs may increase patients’ risk of cancer.
January 13, 2020
Global-reach-rx-drug-news

Numbrino Approved as a Local Anesthetic

January 13, 2020 – The U.S. FDA has approved Numbrino® (cocaine hydrochloride nasal solution 4%), a nasal spray manufactured by Lanett Company and indicated to provide local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.